A Cross-Sectional Study of the Prevalence of Cardiac Valvular Abnormalities in Hyperprolactinemic Patients Treated With Ergot-Derived Dopamine Agonists
Context: Concern exists in the literature that the long-term use of ergot-derived dopamine agonist drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease. Objective: The aim of the study was to determine the prevalence of valvular heart abn...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2014-01, Vol.99 (1), p.90-96 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 1 |
| container_start_page | 90 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 99 |
| creator | Drake, W. M Stiles, C. E Howlett, T. A Toogood, A. A Bevan, J. S Steeds, R. P |
| description | Context:
Concern exists in the literature that the long-term use of ergot-derived dopamine agonist drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease.
Objective:
The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking dopamine agonists as treatment for lactotrope pituitary tumors and to explore any associations with the cumulative dose of drug used.
Design:
A cross-sectional echocardiographic study was performed in a large group of patients who were receiving dopamine agonist therapy for hyperprolactinemia. Studies were performed in accordance with the British Society of Echocardiography minimum dataset for a standard adult transthoracic echocardiogram. Poisson regression was used to calculate relative risks according to quartiles of dopamine agonist cumulative dose using the lowest cumulative dose quartile as the reference group.
Setting:
Twenty-eight centers of secondary/tertiary endocrine care across the United Kingdom participated in the study.
Results:
Data from 747 patients (251 males; median age, 42 y; interquartile range [IQR], 34–52 y) were collected. A total of 601 patients had taken cabergoline alone; 36 had been treated with bromocriptine alone; and 110 had received both drugs at some stage. The median cumulative dose for cabergoline was 152 mg (IQR, 50–348 mg), and for bromocriptine it was 7815 mg (IQR, 1764–20 477 mg). A total of 28 cases of moderate valvular stenosis or regurgitation were observed in 24 (3.2%) patients. No associations were observed between cumulative doses of dopamine agonist used and the age-corrected prevalence of any valvular abnormality.
Conclusion:
This large UK cross-sectional study does not support a clinically concerning association between the use of dopamine agonists for the treatment of hyperprolactinemia and cardiac valvulopathy. |
| doi_str_mv | 10.1210/jc.2013-2254 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5137780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24187407</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5035-277a837bada9bdc5baea5302366a18daebe4a357cc1e670db4dfc98556970b373</originalsourceid><addsrcrecordid>eNptkU1vEzEQhlcIREPhxhn5wq1b7LW93r0gRWmhSJWo1PJxs2a9k8TBWa9sb6r8Ev4ujlIKSFiyLM88885o3qJ4zeg5qxh9tzHnFWW8rCopnhQz1gpZKtaqp8WM0oqVraq-nxQvYtxQyoSQ_HlxUgnWKEHVrPg5J4vgYyxv0STrB3DkNk39nvglSWskNwF34HAweIgsIPQWDPkKbjc5CGTeDT5swdlkMRI7kKv9iGEM3kGWG3BrDbmBnBxSJHcBIWFPvtm0Jpdh5VN5gcHucujCj7DNPJmv_GBjii-LZ0twEV89vKfFlw-Xd4ur8vrzx0-L-XVpJOWyrJSChqsOemi73sgOECSnFa9rYE0P2KEALpUxDGtF-070S9M2Utatoh1X_LR4f9Qdp26LvcmDBnB6DHYLYa89WP1vZrBrvfI7LRlXqqFZ4OwoYA5rDLh8rGVUHwzSG6MPBumDQRl_83e_R_i3Ixl4-wBANOCWAQZj4x-uYXWleJ05ceTuvUsY4g833WPQawSX1prmI2rVlLmzoCz_ynyZzGX8WIZD703IKx8Dxqg3fgrZ_Pj_qX8BsAa97A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Cross-Sectional Study of the Prevalence of Cardiac Valvular Abnormalities in Hyperprolactinemic Patients Treated With Ergot-Derived Dopamine Agonists</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Drake, W. M ; Stiles, C. E ; Howlett, T. A ; Toogood, A. A ; Bevan, J. S ; Steeds, R. P</creator><creatorcontrib>Drake, W. M ; Stiles, C. E ; Howlett, T. A ; Toogood, A. A ; Bevan, J. S ; Steeds, R. P ; UK Dopamine Agonist Valvulopathy Group</creatorcontrib><description>Context:
Concern exists in the literature that the long-term use of ergot-derived dopamine agonist drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease.
Objective:
The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking dopamine agonists as treatment for lactotrope pituitary tumors and to explore any associations with the cumulative dose of drug used.
Design:
A cross-sectional echocardiographic study was performed in a large group of patients who were receiving dopamine agonist therapy for hyperprolactinemia. Studies were performed in accordance with the British Society of Echocardiography minimum dataset for a standard adult transthoracic echocardiogram. Poisson regression was used to calculate relative risks according to quartiles of dopamine agonist cumulative dose using the lowest cumulative dose quartile as the reference group.
Setting:
Twenty-eight centers of secondary/tertiary endocrine care across the United Kingdom participated in the study.
Results:
Data from 747 patients (251 males; median age, 42 y; interquartile range [IQR], 34–52 y) were collected. A total of 601 patients had taken cabergoline alone; 36 had been treated with bromocriptine alone; and 110 had received both drugs at some stage. The median cumulative dose for cabergoline was 152 mg (IQR, 50–348 mg), and for bromocriptine it was 7815 mg (IQR, 1764–20 477 mg). A total of 28 cases of moderate valvular stenosis or regurgitation were observed in 24 (3.2%) patients. No associations were observed between cumulative doses of dopamine agonist used and the age-corrected prevalence of any valvular abnormality.
Conclusion:
This large UK cross-sectional study does not support a clinically concerning association between the use of dopamine agonists for the treatment of hyperprolactinemia and cardiac valvulopathy.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2013-2254</identifier><identifier>PMID: 24187407</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adult ; Biological and medical sciences ; Cross-Sectional Studies ; Dopamine Agonists - therapeutic use ; Echocardiography ; Endocrinopathies ; Ergolines - therapeutic use ; Ergot Alkaloids - therapeutic use ; Feeding. Feeding behavior ; Female ; Fundamental and applied biological sciences. Psychology ; Heart Valve Diseases - chemically induced ; Heart Valve Diseases - diagnostic imaging ; Heart Valve Diseases - epidemiology ; Humans ; Hyperprolactinemia - diagnostic imaging ; Hyperprolactinemia - drug therapy ; Hyperprolactinemia - epidemiology ; Male ; Medical sciences ; Middle Aged ; Prevalence ; United Kingdom - epidemiology ; Vertebrates: anatomy and physiology, studies on body, several organs or systems ; Vertebrates: endocrinology</subject><ispartof>The journal of clinical endocrinology and metabolism, 2014-01, Vol.99 (1), p.90-96</ispartof><rights>Copyright © 2014 by The Endocrine Society</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5035-277a837bada9bdc5baea5302366a18daebe4a357cc1e670db4dfc98556970b373</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28162736$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24187407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drake, W. M</creatorcontrib><creatorcontrib>Stiles, C. E</creatorcontrib><creatorcontrib>Howlett, T. A</creatorcontrib><creatorcontrib>Toogood, A. A</creatorcontrib><creatorcontrib>Bevan, J. S</creatorcontrib><creatorcontrib>Steeds, R. P</creatorcontrib><creatorcontrib>UK Dopamine Agonist Valvulopathy Group</creatorcontrib><title>A Cross-Sectional Study of the Prevalence of Cardiac Valvular Abnormalities in Hyperprolactinemic Patients Treated With Ergot-Derived Dopamine Agonists</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Context:
Concern exists in the literature that the long-term use of ergot-derived dopamine agonist drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease.
Objective:
The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking dopamine agonists as treatment for lactotrope pituitary tumors and to explore any associations with the cumulative dose of drug used.
Design:
A cross-sectional echocardiographic study was performed in a large group of patients who were receiving dopamine agonist therapy for hyperprolactinemia. Studies were performed in accordance with the British Society of Echocardiography minimum dataset for a standard adult transthoracic echocardiogram. Poisson regression was used to calculate relative risks according to quartiles of dopamine agonist cumulative dose using the lowest cumulative dose quartile as the reference group.
Setting:
Twenty-eight centers of secondary/tertiary endocrine care across the United Kingdom participated in the study.
Results:
Data from 747 patients (251 males; median age, 42 y; interquartile range [IQR], 34–52 y) were collected. A total of 601 patients had taken cabergoline alone; 36 had been treated with bromocriptine alone; and 110 had received both drugs at some stage. The median cumulative dose for cabergoline was 152 mg (IQR, 50–348 mg), and for bromocriptine it was 7815 mg (IQR, 1764–20 477 mg). A total of 28 cases of moderate valvular stenosis or regurgitation were observed in 24 (3.2%) patients. No associations were observed between cumulative doses of dopamine agonist used and the age-corrected prevalence of any valvular abnormality.
Conclusion:
This large UK cross-sectional study does not support a clinically concerning association between the use of dopamine agonists for the treatment of hyperprolactinemia and cardiac valvulopathy.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cross-Sectional Studies</subject><subject>Dopamine Agonists - therapeutic use</subject><subject>Echocardiography</subject><subject>Endocrinopathies</subject><subject>Ergolines - therapeutic use</subject><subject>Ergot Alkaloids - therapeutic use</subject><subject>Feeding. Feeding behavior</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart Valve Diseases - chemically induced</subject><subject>Heart Valve Diseases - diagnostic imaging</subject><subject>Heart Valve Diseases - epidemiology</subject><subject>Humans</subject><subject>Hyperprolactinemia - diagnostic imaging</subject><subject>Hyperprolactinemia - drug therapy</subject><subject>Hyperprolactinemia - epidemiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>United Kingdom - epidemiology</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><subject>Vertebrates: endocrinology</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1vEzEQhlcIREPhxhn5wq1b7LW93r0gRWmhSJWo1PJxs2a9k8TBWa9sb6r8Ev4ujlIKSFiyLM88885o3qJ4zeg5qxh9tzHnFWW8rCopnhQz1gpZKtaqp8WM0oqVraq-nxQvYtxQyoSQ_HlxUgnWKEHVrPg5J4vgYyxv0STrB3DkNk39nvglSWskNwF34HAweIgsIPQWDPkKbjc5CGTeDT5swdlkMRI7kKv9iGEM3kGWG3BrDbmBnBxSJHcBIWFPvtm0Jpdh5VN5gcHucujCj7DNPJmv_GBjii-LZ0twEV89vKfFlw-Xd4ur8vrzx0-L-XVpJOWyrJSChqsOemi73sgOECSnFa9rYE0P2KEALpUxDGtF-070S9M2Utatoh1X_LR4f9Qdp26LvcmDBnB6DHYLYa89WP1vZrBrvfI7LRlXqqFZ4OwoYA5rDLh8rGVUHwzSG6MPBumDQRl_83e_R_i3Ixl4-wBANOCWAQZj4x-uYXWleJ05ceTuvUsY4g833WPQawSX1prmI2rVlLmzoCz_ynyZzGX8WIZD703IKx8Dxqg3fgrZ_Pj_qX8BsAa97A</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Drake, W. M</creator><creator>Stiles, C. E</creator><creator>Howlett, T. A</creator><creator>Toogood, A. A</creator><creator>Bevan, J. S</creator><creator>Steeds, R. P</creator><general>Endocrine Society</general><general>Copyright by The Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>201401</creationdate><title>A Cross-Sectional Study of the Prevalence of Cardiac Valvular Abnormalities in Hyperprolactinemic Patients Treated With Ergot-Derived Dopamine Agonists</title><author>Drake, W. M ; Stiles, C. E ; Howlett, T. A ; Toogood, A. A ; Bevan, J. S ; Steeds, R. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5035-277a837bada9bdc5baea5302366a18daebe4a357cc1e670db4dfc98556970b373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cross-Sectional Studies</topic><topic>Dopamine Agonists - therapeutic use</topic><topic>Echocardiography</topic><topic>Endocrinopathies</topic><topic>Ergolines - therapeutic use</topic><topic>Ergot Alkaloids - therapeutic use</topic><topic>Feeding. Feeding behavior</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart Valve Diseases - chemically induced</topic><topic>Heart Valve Diseases - diagnostic imaging</topic><topic>Heart Valve Diseases - epidemiology</topic><topic>Humans</topic><topic>Hyperprolactinemia - diagnostic imaging</topic><topic>Hyperprolactinemia - drug therapy</topic><topic>Hyperprolactinemia - epidemiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>United Kingdom - epidemiology</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drake, W. M</creatorcontrib><creatorcontrib>Stiles, C. E</creatorcontrib><creatorcontrib>Howlett, T. A</creatorcontrib><creatorcontrib>Toogood, A. A</creatorcontrib><creatorcontrib>Bevan, J. S</creatorcontrib><creatorcontrib>Steeds, R. P</creatorcontrib><creatorcontrib>UK Dopamine Agonist Valvulopathy Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drake, W. M</au><au>Stiles, C. E</au><au>Howlett, T. A</au><au>Toogood, A. A</au><au>Bevan, J. S</au><au>Steeds, R. P</au><aucorp>UK Dopamine Agonist Valvulopathy Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Cross-Sectional Study of the Prevalence of Cardiac Valvular Abnormalities in Hyperprolactinemic Patients Treated With Ergot-Derived Dopamine Agonists</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2014-01</date><risdate>2014</risdate><volume>99</volume><issue>1</issue><spage>90</spage><epage>96</epage><pages>90-96</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>Context:
Concern exists in the literature that the long-term use of ergot-derived dopamine agonist drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease.
Objective:
The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking dopamine agonists as treatment for lactotrope pituitary tumors and to explore any associations with the cumulative dose of drug used.
Design:
A cross-sectional echocardiographic study was performed in a large group of patients who were receiving dopamine agonist therapy for hyperprolactinemia. Studies were performed in accordance with the British Society of Echocardiography minimum dataset for a standard adult transthoracic echocardiogram. Poisson regression was used to calculate relative risks according to quartiles of dopamine agonist cumulative dose using the lowest cumulative dose quartile as the reference group.
Setting:
Twenty-eight centers of secondary/tertiary endocrine care across the United Kingdom participated in the study.
Results:
Data from 747 patients (251 males; median age, 42 y; interquartile range [IQR], 34–52 y) were collected. A total of 601 patients had taken cabergoline alone; 36 had been treated with bromocriptine alone; and 110 had received both drugs at some stage. The median cumulative dose for cabergoline was 152 mg (IQR, 50–348 mg), and for bromocriptine it was 7815 mg (IQR, 1764–20 477 mg). A total of 28 cases of moderate valvular stenosis or regurgitation were observed in 24 (3.2%) patients. No associations were observed between cumulative doses of dopamine agonist used and the age-corrected prevalence of any valvular abnormality.
Conclusion:
This large UK cross-sectional study does not support a clinically concerning association between the use of dopamine agonists for the treatment of hyperprolactinemia and cardiac valvulopathy.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>24187407</pmid><doi>10.1210/jc.2013-2254</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2014-01, Vol.99 (1), p.90-96 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5137780 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete |
| subjects | Adult Biological and medical sciences Cross-Sectional Studies Dopamine Agonists - therapeutic use Echocardiography Endocrinopathies Ergolines - therapeutic use Ergot Alkaloids - therapeutic use Feeding. Feeding behavior Female Fundamental and applied biological sciences. Psychology Heart Valve Diseases - chemically induced Heart Valve Diseases - diagnostic imaging Heart Valve Diseases - epidemiology Humans Hyperprolactinemia - diagnostic imaging Hyperprolactinemia - drug therapy Hyperprolactinemia - epidemiology Male Medical sciences Middle Aged Prevalence United Kingdom - epidemiology Vertebrates: anatomy and physiology, studies on body, several organs or systems Vertebrates: endocrinology |
| title | A Cross-Sectional Study of the Prevalence of Cardiac Valvular Abnormalities in Hyperprolactinemic Patients Treated With Ergot-Derived Dopamine Agonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A27%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Cross-Sectional%20Study%20of%20the%20Prevalence%20of%20Cardiac%20Valvular%20Abnormalities%20in%20Hyperprolactinemic%20Patients%20Treated%20With%20Ergot-Derived%20Dopamine%20Agonists&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Drake,%20W.%20M&rft.aucorp=UK%20Dopamine%20Agonist%20Valvulopathy%20Group&rft.date=2014-01&rft.volume=99&rft.issue=1&rft.spage=90&rft.epage=96&rft.pages=90-96&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.2013-2254&rft_dat=%3Cpubmed_cross%3E24187407%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24187407&rfr_iscdi=true |